The Frontier Goes to Whoever Shows Up

The contest in biotechnology does not wait at the border. It is fought at the frontier of discovery, where the standards, the data, and the platforms that will govern the field get decided. That ground is contested now. The question for American policy is whether the United States holds its position or retreats.

Start with the threat. A determined adversary is directing state resources at the next generation of biotechnology with a clear objective. Set the standards. Hold the data. Own the platforms. A rival that controls the frontier sets the terms of the contest for everyone else. Left unanswered, that is a national security problem of the first order.

Now the danger in our own response. One answer gaining ground in Washington treats American capital at the frontier as the threat itself. The move is to fold biotechnology into the COINS Act, the outbound-investment regime that already screens American money flowing to Chinese semiconductors, artificial intelligence, and quantum. Extend that screen to biotech and U.S. licensing, joint ventures, and equity tied to Chinese biotech, which fall under Treasury review. It advances on two tracks at once. A Treasury rule in drafting and legislation written to force it. The concern is legitimate. The approach is the problem.

A broad restriction on engagement does not starve the adversary. It isolates the United States. Pull American capital and researchers back from early cross-border science, and two consequences follow. The country loses visibility into the work that will define the field, the proximity that reveals what a competitor is building before it matures. And the ground American investors vacate does not stay empty. Allied and European partners who operate under no such limits fill it. The frontier goes to whoever shows up. A power does not have to be outspent to lose its lead. It can simply withdraw.

The pattern is familiar. The United States let its position in semiconductors, shipbuilding, and critical minerals slip overseas, and in each case, a competitor stood ready to fill the space. Bar an American company from a market on security grounds, and a foreign rival writes the global standard in its place. The exclusion reads as protection. The result is a weaker hand.

There is a way to meet the real threat that does not run through a new screen on American capital. The genuine dangers are narrow, and the law already reaches them. They do not call for a fresh regime that treats engagement itself as the hazard. Strength is the answer here. Restriction is not. Invest in the research base, the manufacturing, and the workforce that carry American discovery forward. Diversify the supply to trusted and allied nations so that no single point of failure lies within a competitor's borders. Hold American presence at the frontier, because that presence is a security asset in its own right. Strength compounds. A wall only surrenders ground.

Security and engagement run together. The power that stays at the frontier, with its eyes open and its standards in play, is the one that stays safe. ABI will keep making that case and will be specific about which policies meet the threat and which only appear to do so.

This is the fight worth following. Subscribe to ABI's analysis as it publishes.